Compression behaviour of Erling Shitong Powder Veterinary Grade API in a rotary tablet press line is governed by the interaction between its particle size distribution, moisture content, and the selected filler-binder system. For direct compression, a formulation containing 10% w/w API, 45% w/w microcrystalline cellulose (Ph. Eur. 4.04, USP-NF), 35% w/w lactose monohydrate, 4% w/w crospovidone, 1% w/w magnesium stearate, and 0.5% w/w colloidal silicon dioxide is blended in a bin blender at 10 rpm for 20 min. The API lot should be pre-sieved through a 0.5 mm screen to eliminate agglomerates. On a 16-station rotary tablet press with 10 mm round tooling, pre-compression is set at 5 kN and main compression at 14 kN. Tablets of 250 mg target weight achieve hardness 7 kp, friability 0.6% per USP <1216>, and disintegration 12 min in water at 37°C per USP <701>. When the API content is reduced to 1% w/w, blend uniformity becomes the critical process parameter; a 60 L bin blender charge at 70% fill volume with a 30 min mixing cycle typically yields a relative standard deviation below 5.0%. For moisture-sensitive lots, aqueous wet granulation is replaced by dry granulation using roll compaction at 0.8 mm screen gap and 12 kN/cm roll force, followed by milling through a 1.0 mm conical mill. The granulated material is blended with 0.5% w/w magnesium stearate and compressed at 16 kN, producing tablets with hardness 8 kp and friability 0.4%. Acceptance for blend uniformity follows USP <905> with an acceptance value not exceeding 15.0. In-process weight and hardness are monitored every 15 min; a drift in hardness beyond ±1 kp requires adjustment of fill depth or compression force. Tablet dissolution is evaluated per USP <711> with a Q value of 75% at 45 min in 900 mL of 0.1 N hydrochloric acid at 37°C. Where published data for this specific API configuration is limited, process windows are transferred from veterinary solid oral dosage forms with similar particle size and moisture sensitivity.

What Limits Sterile Filtration of Veterinary Injectable Solutions Containing Erling Shitong Powder?

Sterile filtration of a veterinary injectable solution requires complete dissolution of the API powder in Water for Injection at a concentration commonly between 10 mg/mL and 100 mg/mL. The solution pH is adjusted to 6.0–6.5 with 0.1 N hydrochloric acid or sodium hydroxide; buffering with phosphate salts is avoided when the active molecule forms insoluble phosphate complexes. If aqueous solubility is insufficient, a cosolvent system of 10–30% v/v propylene glycol or 5–10% v/v ethanol is used, but terminal sterilization then requires validation of residual solvent limits under USP <467>. The bulk solution is prefiltered through a 0.45 μm polyethersulfone capsule filter and subsequently through a 0.22 μm membrane filter rated per ASTM F838-20 for bacterial retention. Filtration pressure is maintained below 1.5 bar to prevent particle shedding and filter integrity failure. Filter integrity is verified by bubble point or diffusive flow test before and after filtration. Aseptic filling of 100 mL type II glass vials occurs under ISO 14644-1:2015 Class 5 conditions with Grade A laminar airflow; stopper closure integrity is tested by dye ingress per USP <1207>. For heat-stable formulations, terminal sterilization at 121°C for 15 min with a minimum F₀ of 8.0 is preferred. The finished solution is tested for sterility per USP <71>, bacterial endotoxins per USP <85> with a limit of 0.5 EU/mL, and particulate matter per USP <788>. For small-volume parenterals, the limit is 6000 particles per container at ≥10 μm and 600 particles per container at ≥25 μm. Light protection is required when the API shows photodegradation; amber vials or secondary cartons are specified. Incompatibility with polyvalent cations and strong oxidizing agents requires dedicated stainless steel 316L mixing and transfer lines with passivated surfaces per ASME BPE.

Low-Dose Capsule Filling Without Pre-Rolling: Powder Rheology and Electrostatic Control

Powder blend homogeneity for low-dose capsule filling is primarily determined by the API particle size and electrostatic charge. For a 10 mg dose in a size 3 capsule, the API is geometrically diluted with lactose monohydrate in a 5:1 carrier-to-API first step, then combined with 0.5% w/w sodium stearyl fumarate and 0.25% w/w colloidal silicon dioxide. The final blend is mixed in a 600 L bin blender at 8 rpm for 25 min. Flow parameters measured before filling include angle of repose below 35°, Carr index below 20%, and Hausner ratio below 1.25. A dosator-type capsule filler operating at 6000 capsules/h is used; powder bed height is kept above 70% of the feed shoe capacity to avoid low-weight capsules. Fill weight is verified at 15 min intervals with a target weight of 250 mg and an acceptable deviation of ±5%. Uniformity of dosage units is assessed per USP <905> with an acceptance value not exceeding 15.0. Dissolution testing per USP <711> is performed in 900 mL of 0.1 N hydrochloric acid at 37°C and 50 rpm paddle speed, with a Q value of 75% at 30 min. Capsule shell moisture content is controlled between 12% and 15%; below this range, brittleness causes shell cracking during filling, while above it, softening causes dimpling. For hygroscopic API lots, HPMC capsules are substituted for gelatin and packaged with a 1.0 g silica gel desiccant in HDPE bottles with induction-sealed closures. Electrostatic adhesion to stainless steel contact surfaces is reduced by maintaining relative humidity at 40–50% in the filling suite; antistatic ionizing bars are positioned over the feed frame.

For drinking-water administration in poultry and swine, the API powder is converted into a buffered soluble powder or oral solution. A representative soluble powder formula contains 20% w/w API, 60% w/w lactose monohydrate, 5% w/w citric acid anhydrous, 2% w/w sodium citrate dihydrate, 3% w/w povidone K25, and 10% w/w dextrose. The dry components are sifted through a 0.5 mm mesh and blended in a V-blender at 15 rpm for 30 min. The API is milled to a d90 below 75 μm before blending to ensure dispersion. Dissolution of 1 g of powder in 100 mL of water at 25°C must yield a clear to slightly opalescent liquid within 3 min; no undissolved particles larger than 150 μm may remain on a 100-mesh screen. The citric acid-sodium citrate buffer maintains pH between 4.0 and 5.5 after dilution, a range that balances API solubility and chemical stability in solution for 24 h at 25°C. Chlorinated water can oxidize the active molecule; therefore, the reconstitution instruction specifies deionized or boiled water cooled to 25°C. The finished powder is packed in triple-layer foil-lined bags with residual moisture not exceeding 2.0%; exposure to relative humidity above 60% causes caking. For oral solution manufacturing, the API is dissolved first in 70% of the final volume of purified water, pH-adjusted, and then made to volume in a stainless steel 316L mixing tank. The solution is filtered through a 10 μm cartridge filter before filling into amber HDPE bottles. In-use stability is limited to 24 h after reconstitution; beyond this period, the active content may fall below 95% of label claim.

Granulation Endpoint Detection Using Impeller Power Draw and Near-Infrared Moisture Probes

Wet granulation of the API in a high-shear mixer is monitored by impeller power draw and near-infrared moisture probes to fix the endpoint. A typical granulation charge contains 5% w/w API, 25% w/w microcrystalline cellulose, 35% w/w lactose monohydrate, 4% w/w povidone K30, and 31% w/w corn starch. Purified water is sprayed at a rate of 20 mL/min per kg dry mass while the impeller rotates at 250 rpm and the chopper at 1800 rpm. The power draw curve rises from a dry-mix baseline of 1.2 kW to a wet-mass peak of 2.8 kW; the endpoint is defined as 85–90% of the peak-to-baseline span on the descending side. Simultaneously, near-infrared reflectance at the mixer bowl indicates a moisture content of 8–10% w/w. Over-granulation above 12% w/w moisture produces dense granules that extend disintegration beyond 15 min. The wet mass is discharged through a 2.0 mm sieve and dried in a fluid bed dryer with inlet air at 65°C to a final loss on drying of 1.5–2.5%. Dried granules are milled through a 1.2 mm conical screen and blended with 1% w/w magnesium stearate for 3 min. The resulting granules are filled into sachets or compressed into tablets. If the API is thermolabile, inlet air is reduced to 50°C and drying time is extended from 20 min to 45 min. The batch record requires documentation of impeller power draw, inlet air dew point below 5°C, and near-infrared spectral moisture at three bowl locations. This method is preferred when the API has poor flow and high dust generation, since direct compression would lead to segregation and insufficient tablet weight uniformity.

Sterile powder fill for reconstitution is selected when the API exhibits unacceptable hydrolysis in aqueous solutions at 25°C within 24 h. The API powder is sterilized by dry heat at 160°C for 2 h if thermostable, or by aseptic crystallization followed by milling under ISO 14644-1:2015 Class 5 conditions. The sterile powder is filled into 10 mL type I glass vials at a target weight of 500 mg using a vacuum-assisted auger filler inside an aseptic isolator. Residual moisture is controlled below 2.0%; higher levels accelerate solid-state degradation and reduce reconstitution performance. The powder is reconstituted with 5 mL Water for Injection to a concentration of 100 mg/mL. Reconstitution time must not exceed 60 s with gentle swirling; undissolved particles are assessed per USP <788> after 5 min. The reconstituted solution is intended for immediate use because chemical stability at 25°C is limited to 6 h. Sterility testing follows USP <71>, bacterial endotoxin limit is 0.5 EU/mL after reconstitution, and container closure integrity is verified by vacuum decay per USP <1207>. The fill weight uniformity across the batch is monitored with statistical process control; a relative standard deviation above 2.0% triggers line adjustment. For lyophilized formulations, the API is dissolved at 50 mg/mL with 5% w/v mannitol and 2% w/v trehalose as bulking and lyoprotectant agents. The solution is filled into 20 mL vials, lyophilized with a shelf temperature ramp from −40°C to 25°C over 36 h, and sealed under vacuum. The resulting cake contains 1.0–2.0% residual moisture and dissolves within 2 min upon reconstitution.

When Erling Shitong Powder Is Dispersed in Non-Sterile Feed Premix: Segregation Control and Stability Boundaries

Dispersion of a micronized API into a non-sterile feed premix creates segregation risks that are controlled through stepwise dilution and particle size matching. The first dilution is prepared at 5% w/w API in lactose monohydrate and mixed in a 100 kg ribbon blender at 20 rpm for 10 min. This intermediate is then diluted to a final premix concentration of 0.5–2.0% w/w using a carrier system of 40% w/w ground corn cob, 30% w/w lactose, 20% w/w wheat middlings, and 10% w/w mineral oil. The mineral oil is sprayed onto the carrier before adding the API dilution to bind fine particles and reduce dust. Mixing uniformity is tested at 10 sampling points using a thief sampler; the coefficient of variation must remain below 5.0%. Segregation potential is assessed by sampling the top, middle, and bottom of the blender after 15 min dwell time. If API particle size d90 exceeds 200 μm while carrier particles are below 100 μm, the API fraction migrates downward and the top-layer assay falls below 90% of target. The premix is packaged in 25 kg multiwall paper bags with a polyethylene liner; storage at 25°C and 60% relative humidity is recommended. Moisture ingress above 8% w/w in the premix promotes caking and mold growth. The premix is mixed into complete feed at a rate of 1–5 kg/tonne to achieve the intended therapeutic dose. Regulatory compliance for medicated feed follows 21 CFR 225.1 and 21 CFR 225.130 for cGMP in medicated feed manufacturing, including equipment cleanout, flush material management, and batch record documentation. Carryover risk is evaluated by analyzing the first 5 kg of the subsequent batch for API residue; acceptance is below 0.1% of the previous batch concentration. When the API is sensitive to heat and moisture, the premix should not be pelleted above 70°C; steam conditioning at 80°C for 30 s may reduce potency by more than 10%. In such cases, the premix is applied as a top-dress or used in mash feed to preserve activity.